Gyros Protein Technologies Launches Advanced HEK293 Host Cell Protein Detection Kits
A leading protein technology company, Gyros Protein Technologies AB, has recently unveiled their new Gyrolab® HEK293 HCP Type SN and CL Kit Reagents in a strategic partnership with BioGenes GmbH. These innovative kits offer a highly sensitive and efficient solution for detecting host cell proteins (HCPs) in biotherapeutics produced using HEK293 cell lines.
The Importance of Removing Host Cell Proteins in Biopharmaceuticals
The removal of host cell proteins (HCPs) from biotherapeutics is a critical step in their development. HCP residuals can trigger unwanted immune responses in patients, ranging from mild allergies to severe immunological reactions. Ensuring their removal is essential for maintaining the quality, consistency, and stability of biotherapeutics, ensuring patient safety.
Details on the New Gyrolab Kits
Gyros Protein Technologies’ new kits offer a validated solution for HCP detection in biotherapeutics derived from HEK293 cells. Featuring improved sensitivity and broad antibody coverage, these kits are designed to work seamlessly with the Gyrolab automated immunoassay platform.
These off-the-shelf, plug-and-play kits minimize reagent consumption and sample volume, enhancing analytical efficiency and streamlining workflow productivity. The introduction of these comprehensive kits underscores Gyros Protein Technologies’ commitment to expanding its applications within the biopharmaceutical industry.
Collaborative Approach with BioGenes GmbH
The new kits incorporate BioGenes GmbH’s 360-HCP antibodies, known for their wide-ranging antigen coverage. Developed through a unique process, these antibodies are produced by immunizing various species, ensuring high-quality antibody preparations optimized for detection.
The collaboration between Gyros Protein Technologies and BioGenes GmbH exemplifies a synergistic relationship targeting the paramount importance of patient safety and drug efficacy in biopharmaceutical development.
Expert Insights on the New Kits
“Gyrolab HEK293 HCP Type SN Kit Reagents and Gyrolab HEK293 HCP Type CL Kit Reagents are valuable additions to our portfolio of HCP impurity kits. Our ready-to-use kits provide a rapid, reliable, and sensitive solution for customers developing essential new biotherapeutics. The introduction of these new kits highlights our continuous investment in expanded applications for our industry-leading Gyrolab systems.”
Mark Vossenaar, General Manager, Biopharmaceutical Development Division, Gyros Protein Technologies
We are excited that the HEK293/360 ELISA kits are now optimized for use with Gyrolab technology. This collaboration provides a valuable tool for process optimization, and we believe that great results can be achieved through this combined strategy. Together, we are enabling orthogonal methods for drug development, increasing the chances of successful market authorization while also improving drug efficacy and patient safety.”
Dr. Alexander Knoll, CEO, BioGenes GmbH
Conclusion
Gyros Protein Technologies’ innovative HEK293 HCP detection kits, developed in collaboration with BioGenes GmbH, offer a game-changer in the field of biopharmaceutical development. By providing a rapid and sensitive method for detecting host cell proteins, these kits contribute towards ensuring the safety and efficacy of emerging biotherapeutics.
From enhanced antibody coverage to reduced reagent consumption, the Gyrolab HEK293 HCP kits represent a significant leap forward in automated immunoassay technology.
Stay informed about the latest advances in protein technology and biopharmaceutical development. Share your thoughts and insights in the comments below!